Last updated on: 19/05/2010
Name of organisation
1) Department/Research groupPharmacoepidemiology Erasmus University
2) Organisation/affiliationErasmus University Medical Center
Short Name in the inventoryErasmus MC Pharmacoepi
Administrative Contact
Title Professor
Last name Sturkenboom
First name Miriam
Address line 1POBOX 2040
Address line 2dep. Medical Informatics
Address line 3
CityRotterdam
Postcode3000 CA
CountryNetherlands
Phone number (incl. country code)31-10-7044123
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Professor
Last name Sturkenboom
First name Miriam
Address line 1POBOX 2040
Address line 2dep. Medical Informatics
Address line 3
CityRotterdam
Postcode3000 CA
CountryNetherlands
Phone number (incl. country code)31-10-7044123
Alternative phone number
Fax number (incl. country code)
2. Description
The Pharmacoepidemiology Group at Erasmus Univerisity is one of the world leading groups in terms of use of electronic medical record databases for pharmacoepidemiological studies and in pharmacogenetics. The group is spread over two departments: Medical Informatics which focuses on use of health care data to study effects of drugs and the department of Epidemiology that focuses on pharmacogenetics by using data from the Rotterdam cohort.
The department of Medical Informatics has set up the Integrated Primary Care Information database with 1 million patients, and it is coordinating several EC funded drug safety projects such as EU-ADR, ARITMO, SOS that aim to link data across the EU for safety signal generation and hypothesis testing.
The group is headed by prof. M. Sturkenboom and prof. B. Stricker and has 8 staff persons and more than 20 PhD students. The group is annually producing more than 50 peer reviewed publications in the area of pharmacoepidemiology and pharmacogenetics.
3. Category
University based
Hospital based
Charity or non-profit organisation
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
No
Statistician
Yes
No
Clinician
Yes
No
Clinical Pharmacologist
Yes
No
Pharmacist
Yes
No
Geneticist/Pharmacogeneticist
Yes
No
IT specialist
Yes
No
Ethics expertise
Yes
No
Legal expertise
Yes
No
Regulatory expertise
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Devices
Disorders of the central nervous system
Ear, nose and oropharynx disorders
Endocrine disorders
Eye disorders
Gastrointestinal tract
Geriatrics
Immunological products and vaccines
Infectious diseases
Liver disease
Malignant disease
Musculoskeletal and joint diseases
Neonates
Osteoporosis
Paediatrics
Pregnancy
Psychiatry
Renal impairment
Respiratory diseases
Skin disorders
Urinary tract disorders
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Between 150 and 1499
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
No
Interactive voice response systems
Yes
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
IPCI150
GPRD5
THIN5
PHARMO10
HSD10
11. Registries established by centre
Drug RegistryIPCI
Disease RegistryIPCI
Other Rotterdam cohort
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
By EU funding schemes
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Rodenburg EM, Visser LE, Danser AH, Hofman A, van Noord C, Witteman JC, Uitterlinden AG, Stricker BH.
Genetic variance in CYP2C8 and increased risk of myocardial infarction.
Pharmacogenet Genomics. 2010 Apr 29
Trifirò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study.
Ann Intern Med. 2010 Apr 6;152(7):418-25, W139-40.
Trifirò G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, Catania MA, Salvo F, David A, Moore N, Caputi AP, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourrier-Reglat A; EU-ADR group. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84.
Risselada R, Straatman H, van Kooten F, Dippel DW, van der Lugt A, Niessen WJ, Firouzian A, Herings RM, Sturkenboom MC. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009 Aug;40(8):2887-92. Epub 2009 Jun 11.
Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli G, Sen EF, Giaquinto C, Cantarutti L, Baiardi P, Felisi MG, Ceci A, Wong IC; TEDDY European Network of Excellence. Drug use in children: cohort study in three European countries. BMJ. 2008 Nov 24;337:a2245. doi: 10.1136/bmj.a2245
